DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 202 filers reported holding DENALI THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $305,913,328 | +22.2% | 13,174,562 | +8.0% | 0.01% | +16.7% |
| Q1 2024 | $250,341,043 | +1.1% | 12,199,856 | +5.7% | 0.01% | 0.0% |
| Q4 2023 | $247,722,351 | +10.3% | 11,543,446 | +6.0% | 0.01% | 0.0% |
| Q3 2023 | $224,563,657 | -24.7% | 10,885,296 | +7.7% | 0.01% | -25.0% |
| Q2 2023 | $298,236,175 | +36.6% | 10,106,275 | +6.7% | 0.01% | +33.3% |
| Q1 2023 | $218,290,108 | -15.8% | 9,474,397 | +1.6% | 0.01% | -25.0% |
| Q4 2022 | $259,245,210 | -1.8% | 9,322,014 | +8.4% | 0.01% | -11.1% |
| Q3 2022 | $263,880,000 | +2.1% | 8,598,212 | -2.1% | 0.01% | +12.5% |
| Q2 2022 | $258,532,000 | -1.8% | 8,784,632 | +7.3% | 0.01% | +14.3% |
| Q1 2022 | $263,336,000 | -27.2% | 8,185,740 | +0.9% | 0.01% | -22.2% |
| Q4 2021 | $361,741,000 | -5.2% | 8,110,822 | +7.3% | 0.01% | -18.2% |
| Q3 2021 | $381,444,000 | -30.9% | 7,560,837 | +7.5% | 0.01% | -26.7% |
| Q2 2021 | $551,906,000 | +47.2% | 7,036,041 | +7.2% | 0.02% | +36.4% |
| Q1 2021 | $374,830,000 | -29.8% | 6,564,452 | +3.0% | 0.01% | -35.3% |
| Q4 2020 | $534,062,000 | +144.9% | 6,376,078 | +4.8% | 0.02% | +112.5% |
| Q3 2020 | $218,036,000 | +44.1% | 6,085,317 | -2.8% | 0.01% | +33.3% |
| Q2 2020 | $151,309,000 | +64.1% | 6,257,582 | +18.8% | 0.01% | +20.0% |
| Q1 2020 | $92,213,000 | +0.9% | 5,266,356 | +0.4% | 0.01% | +25.0% |
| Q4 2019 | $91,410,000 | +13.7% | 5,247,578 | +0.0% | 0.00% | +33.3% |
| Q3 2019 | $80,382,000 | -24.9% | 5,246,909 | +1.8% | 0.00% | -40.0% |
| Q2 2019 | $106,999,000 | +1.3% | 5,154,097 | +13.3% | 0.01% | 0.0% |
| Q1 2019 | $105,634,000 | +11.8% | 4,549,331 | -0.5% | 0.01% | 0.0% |
| Q4 2018 | $94,469,000 | +31.4% | 4,572,695 | +38.3% | 0.01% | +66.7% |
| Q3 2018 | $71,896,000 | +320.4% | 3,307,050 | +194.9% | 0.00% | +200.0% |
| Q2 2018 | $17,101,000 | -17.6% | 1,121,358 | +6.4% | 0.00% | 0.0% |
| Q1 2018 | $20,753,000 | – | 1,053,938 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 6,860,732 | $190,796,957 | 27.96% |
| ARCH Venture Management, LLC | 3,668,749 | $102,027,910 | 26.13% |
| Casdin Capital, LLC | 1,300,000 | $36,153,000 | 2.80% |
| Flagship Pioneering Inc. | 2,619,968 | $72,861,310 | 2.33% |
| SECTORAL ASSET MANAGEMENT INC | 243,850 | $6,781,469 | 1.31% |
| Yiheng Capital Management, L.P. | 1,014,684 | $28,218,362 | 1.25% |
| Artal Group S.A. | 800,000 | $22,248 | 1.24% |
| Temasek Holdings (Private) Ltd | 6,516,041 | $181,211,100 | 1.06% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $267,004 | 0.93% |
| GILDER GAGNON HOWE & CO LLC | 1,767,142 | $49,144,216 | 0.92% |